CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis

European Respiratory Journal

Volumn 34, Issue 3, 2009, Pages 676-686

  Busuttil, A ^a   Weigt, S S ^a   Keane, M P ^d   Xue, Y Y ^a   Palchevskiy, V ^a   Burdick, M D ^c   Huang, C ^a   Zisman, D A ^a   Fishbein, M ^a   Lynch III, J P ^a   Strieter, R M ^c   Elashoff, R M ^b   Belperio, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Chemokine receptors; Chemokines; Leukocytes; Lung; Sarcoidosis

Indexed keywords

CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIGAND;

ADULT; ARTICLE; CELL LINEAGE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIOID CELL; FEMALE; GENE EXPRESSION; GIANT CELL; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LUNG GRANULOMA; LUNG LAVAGE; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHEMOKINES, CXC; FEMALE; HUMANS; INTERFERONS; LIGANDS; MALE; MIDDLE AGED; RECEPTORS, CXCR3; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX;

EID: 70349104091     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00157508     Document Type: Article

References (41)

1. Boucek MM, Waltz DA, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report - 2006. J Heart Lung Transplant 2006; 25: 893-903. (Pubitemid 44143014)
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
3. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889. (Pubitemid 33152325)
4. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336: 1224-1234.
5. Poletti V, Patelli M, Spiga L, et al. Transbronchial lung biopsy in pulmonary sarcoidosis. Is it an evaluable method in detection of disease activity? Chest 1986; 89: 361-365.
6. Belperio JA, Burdick MD, Keane MP, et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol 2000; 165: 461-472. (Pubitemid 30429540)
7. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969. (Pubitemid 26313554)
8. Keane MP, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis. Chem Immunol 1999; 72: 86-101. (Pubitemid 29403346)
9. Agostini C, Cassatella M, Zambello R, et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998; 161: 6413-6420. (Pubitemid 28536019)
10. Sugiyama K, Mukae H, Ishii H, et al. Elevated levels of interferon γ-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology 2006; 11: 708-714. (Pubitemid 44581434)
11. Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006; 130: 982-988. (Pubitemid 44583725)
12. Nishioka Y, Manabe K, Kishi J, et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol 2007; 149: 317-326. (Pubitemid 47063058)
13. Agostini C, Facco M, Chilosi M, et al. Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation. Microsc Res Tech 2001; 53: 278-287. (Pubitemid 32467165)
14. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121: 32-39.
15. Weigt SS, Elashoff RM, Keane MP, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008; 8: 1512-1522.
16. Belperio JA, Keane MP, Burdick MD, et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005; 115: 1150-1162.
17. Belperio JA, DiGiovine B, Keane MP, et al. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 2002; 73: 591-599. (Pubitemid 34193622)
18. Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996; 157: 910-918. (Pubitemid 26231399)
19. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42. (Pubitemid 20044133)
20. Kreipe H, Radzun HJ, Heidorn K, et al. Proliferation, macrophage colony-stimulating factor, and macrophage colony-stimulating factor-receptor expression of alveolar macrophages in active sarcoidosis. Lab Invest 1990; 62: 697-703. (Pubitemid 20213687)
21. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-4960.
22. Semenzato G, Adami F, Maschio N, et al. Immune mechanisms in interstitial lung diseases. Allergy 2000; 55: 1103-1120. (Pubitemid 30836491)
23. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142: 1268-1271.
24. Rosen Y. Pathology of sarcoidosis. Semin Respir Crit Care Med 2007; 28: 36-52.
25. Lynch JP 3rd, Ma YL, Koss MN, et al. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28: 53-74.
26. Keane MP, Arenberg DA, Lynch JP 3rd, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437-1443.
27. Meloni F, Caporali R, Marone Bianco A, et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 111-118. (Pubitemid 38954751)
28. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J Immunol 2001; 166: 642-649. (Pubitemid 32038488)
29. Beider K, Nagler A, Wald O, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 2003; 102: 1951-1958. (Pubitemid 37122366)
30. Wahlstrom J, Katchar K, Wigzell H, et al. Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 2001; 163: 115-121. (Pubitemid 32097972)
31. Keicho N, Kitamura K, Takaku F, et al. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990; 98: 1125-1129. (Pubitemid 20381274)
32. Lawrence EC, Brousseau KP, Berger MB, et al. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis 1988; 137: 759-764.
33. Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003; 124: 186-195. (Pubitemid 36851351)
34. Prasse A, Georges CG, Biller H, et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol 2000; 122: 241-248. (Pubitemid 30839101)
35. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25: 315-322. (Pubitemid 44922352)
36. Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461.
37. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008; 267: 204-215.
38. de Haas AH, Boddeke HW, Biber K. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 2008; 56: 888-894.
39. de Jong EK, de Haas AH, Brouwer N, et al. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3. J Neurochem 2008; 105: 1726-1736. (Pubitemid 351678495)
40. Li H, Gang Z, Yuling H, et al. Different neurotropic pathogens elicit neurotoxic CCR9- or neurosupportive CXCR3-expressing microglia. J Immunol 2006; 177: 3644-3656. (Pubitemid 44359896)
41. Tanuma N, Sakuma H, Sasaki A, et al. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 2006; 112: 195-204.